Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide
- PMID: 18834950
- DOI: 10.1016/j.biocel.2008.08.039
Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide
Abstract
Alpha-helical peptides, such as T-20 (enfuvirtide) and C34, derived from the gp41 carboxyl-terminal heptad repeat (C-HR) of HIV-1, inhibit membrane fusion of HIV-1 and the target cells. Although T-20 effectively suppresses the replication of multi-drug resistant HIV variants both in vitro and in vivo, prolonged therapy with T-20 induces emergence of T-20 resistant variants. In order to suppress the emergence of such resistant variants, we introduced charged and hydrophilic amino acids, glutamic acid (E) and lysine (K), at the solvent accessible site of C34. In particular, the modified peptide, SC34EK, demonstrates remarkably potent inhibition of membrane fusion by the resistant HIV-1 variants as well as wild-type viruses. The activity was specific to HIV-1 and little influenced by serum components. We found a strong correlation between the anti-HIV-1 activities of these peptides and the thermostabilities of the 6-helix bundles that are formed with these peptides. We also obtained the crystal structure of SC34EK in complex with a 36 amino acid sequence (N36) comprising the amino-terminal heptad repeat of HIV-1. The EK substitutions in the sequence of SC34EK were directed toward the solvent and generated an electrostatic potential, which may result in enhanced alpha-helicity of the peptide inhibitor. The 6-helix bundle complex of SC34EK with N36 appears to be structurally similar to that of C34 and N36. Our approach to enhancing alpha-helicity of the peptide inhibitor may enable future design of highly effective and specific HIV-1 inhibitors.
Similar articles
-
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.Antimicrob Agents Chemother. 2009 Mar;53(3):1013-8. doi: 10.1128/AAC.01211-08. Epub 2008 Dec 29. Antimicrob Agents Chemother. 2009. PMID: 19114674 Free PMC article.
-
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.J Mol Biol. 2004 Jun 25;340(1):9-14. doi: 10.1016/j.jmb.2004.04.027. J Mol Biol. 2004. PMID: 15184018
-
Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.J Virol. 2005 Jan;79(2):764-70. doi: 10.1128/JVI.79.2.764-770.2005. J Virol. 2005. PMID: 15613304 Free PMC article.
-
[The current progress in the development of HIV-1 fusion inhibitors].Yao Xue Xue Bao. 2010 Feb;45(2):184-93. Yao Xue Xue Bao. 2010. PMID: 21351428 Review. Chinese.
-
Resistance to enfuvirtide, the first HIV fusion inhibitor.J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1. J Antimicrob Chemother. 2004. PMID: 15231762 Review.
Cited by
-
Helical peptides with disordered regions for measles viruses provide new generalized insights into fusion inhibitors.iScience. 2024 Jan 17;27(2):108961. doi: 10.1016/j.isci.2024.108961. eCollection 2024 Feb 16. iScience. 2024. PMID: 38333694 Free PMC article.
-
Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.J Biol Chem. 2012 Jun 8;287(24):20281-9. doi: 10.1074/jbc.M112.354126. Epub 2012 Apr 16. J Biol Chem. 2012. PMID: 22511760 Free PMC article.
-
Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.Antivir Chem Chemother. 2015 Apr;24(2):77-82. doi: 10.1177/2040206615614164. Epub 2015 Nov 2. Antivir Chem Chemother. 2015. PMID: 26527820 Free PMC article.
-
Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion.RSC Chem Biol. 2023 Nov 7;5(2):131-140. doi: 10.1039/d3cb00166k. eCollection 2024 Feb 7. RSC Chem Biol. 2023. PMID: 38333196 Free PMC article.
-
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.Biophys J. 2010 Nov 17;99(10):3445-53. doi: 10.1016/j.bpj.2010.09.050. Biophys J. 2010. PMID: 21081094 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials